Novocure has obtained a humanitarian use device designation from the FDA for its Tumor Treating Fields delivery system for use in treating pleural mesothelioma. The company intends to apply for a humanitarian device exemption for the system after it gathers data from the Stellar Phase II pilot trial next year.
FDA grants HUD designation for Novocure's TTFields delivery system
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.